Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Array of light for early disease detection?

23.05.2012
A special feature in the May 11 issue of the journal Science highlights protein array technology, touching on research conducted by Joshua LaBaer, director of the Biodesign Institute’s Virginia G. Piper Center for Personalized Diagnostics.

With the successful completion of the Human Genome Project, research attention is increasingly focusing on proteins. Versatile products produced from genetic templates, proteins are principle actors in both the maintenance of health and the onset of illness. Protein microarrays are a means of bridging the gap between analysis of the nucleotide sequences that make up DNA and the proteome—the universe of proteins built from the amino acids coded for by genes.

Protein microarrays are helping researchers develop early detection methods, particularly for chronic diseases, which account for most of the country’s health care expenditures. Identifying telltale signs of diabetes, coronary artery disease, congestive heart failure and various cancers at an early, pre-symptomatic stage, offers the best prognosis for successful treatment, at dramatically reduced cost.

“Proteins are the machines of biology. Disease is nearly always a result of protein malfunction, and most drugs are designed to affect protein function. Protein microarrays enable us to test the biochemical properties of thousands of proteins simultaneously,” says LaBaer.

While the genome provides the instruction manual for building living systems, proteins are the real molecular workhorses, faithfully carrying out genomic instructions, while also modifying their behavior under myriad environmental influences. Proteins provide structure to cells and tissues, facilitate signaling within and between cells, act as receptors, catalyze enzymatic activity, execute immune functions, and perform countless other biological tasks.

A more thorough understanding of the proteome is therefore vital to diagnostic medicine, particularly for establishing biomarkers—pre-symptomatic indices of early disease states, detectable as protein components in blood. LaBaer’s group is working on discovering biomarkers for a range of deadly illnesses, including, breast, ovarian, lung and oropharyngeal cancers; type I diabetes and assorted infectious pathogens.

Until recently, studying the complexities of proteins, (as opposed to the sequence of four nucleotides making up DNA), has been daunting. A protein microarray usually consists of a library of proteins immobilized on a glass slide or chip in a 2D addressable grid format. Arrays of this sort are made by expressing and painstakingly purifying proteins, then imprinting them onto the slide’s surface. Once a library of proteins has been splayed out on an array, high-throughput methods can be used to investigate their behavior.

Similar arrays have long been used to study DNA, yielding a steady stream of insights into the genome and in some cases providing rapid and accurate diagnostic tools. Researchers would like to repeat the successes of DNA microarrays with protein microarray technology, though a number of hurdles exist. Compared with nucleic acids, proteins exhibit enormous structural diversity and complexity. The synthesis, stabilization and purification of proteins are often laborious undertakings. Adequately attaching proteins to the array surface is tricky and subsequent detection of these proteins through binding events is considerably more complex than in the case of nucleic acid arrays.

Protein microarrays can be broken down into two broad categories. With so-called forward phase arrays, one protein sample is screened against multiple reagents. The capture protein—usually an antibody— is first affixed to the slide surface. The immobilized antibody can then be used to capture antigens it recognizes when a test sample is spread over the array. The test sample could be blood, cells, cell lysates, or some other biological specimen. The captured analyte can then be detected directly, using a fluorescent dye. The technique offers high specificity, but is time consuming.

In reverse phase arrays, the test sample is printed directly on the slide and the array is then detected with a dye-conjugated protein, such as an antibody. One of the key advantages of the reverse phase microarray is a reduction in the number of antibody probes needed to detect a protein antigen. Examples of both forward and reverse arrays are presented in the current Science review.

LaBaer’s group works with a novel protein array, designed in their lab. Known as Nucleic Acid Programmable Protein Array or NAPPA, the technique is particularly powerful because it obviates the need to purify proteins prior to their use in a microarray. Instead of using the protein itself, the NAPPA technique spots protein-coding circular pieces of DNA known as plasmids —the blueprints for building proteins—onto slides, bringing the simplicity and low cost of DNA microarray technology into the world of proteomics.

Immediately prior to the use of the array, an in vitro transcription/translation system is applied as a coating on the slide, turning each array into a nanoscale factory for protein production. Issues of protein stability and purification are avoided, as proteins are synthesized immediately prior to use. (Figure 1 shows a schematic of how NAPPA works.)

“The central concept for NAPPA is to make the proteins ‘fresh’ only moments before testing them and to use the machinery most relevant to the proteins to make them. Currently we are using human ribosomal machinery to make human proteins,” LaBaer says.

LaBaer’s method currently allows some 2300 genes to be arrayed on a conventional microscope slide. Given the vastness of the human proteome, comprised of more than 30,000 distinct proteins, the technique requires around 10 array slides to fully sample the proteome. Spotting DNA plasmids at higher densities requires new imprinting techniques to avoid chemical cross talk between closely situated array spots. Using advanced piezoelectric-pipetting technology, the group anticipates next generation protein arrays that will improve protein densities per slide by roughly an order of magnitude.

Currently, at the Piper Center’s state of the art facility, some 14,000 human proteins are employed in an array in order to detect antibody targets of disease. The technique is being used to investigate posttranslational modifications to proteins and for the identification of novel autoantibodies.

Post-translational changes can occur during or after protein synthesis, resulting in modifications to protein residues. Such changes alter physical and chemical properties affecting protein shape and function. The presence of particular autoantibodies may signal presymptomatic recognition of disease antigens, for example those produced by cancerous tumors. One recent study identified a panel of 28 antigens that can pinpoint early onset breast cancer in blood sera with 80 to 100 percent specificity.

In addition, this research may help speed more effective vaccines to market by identifying immunogenic proteins associated with infectious diseases like cholera, anthrax and Pseudomonas aeruginosa.

“The key to this work,” according top LaBaer, “is to test many patients and many healthy indviduals to determine which responses are specifically found only in the patients. Most important is to confirm these findings in independent experiments. “

Written by: Richard Harth
Science Writer: Biodesign Institute
richard.harth@asu.edu

Joseph Caspermeyer | EurekAlert!
Further information:
http://www.asu.edu

More articles from Health and Medicine:

nachricht Why might reading make myopic?
18.07.2018 | Universitätsklinikum Tübingen

nachricht Unique brain 'fingerprint' can predict drug effectiveness
11.07.2018 | McGill University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

Im Focus: Chemical reactions in the light of ultrashort X-ray pulses from free-electron lasers

Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.

Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

NYSCF researchers develop novel bioengineering technique for personalized bone grafts

18.07.2018 | Life Sciences

Machine-learning predicted a superhard and high-energy-density tungsten nitride

18.07.2018 | Materials Sciences

Why might reading make myopic?

18.07.2018 | Health and Medicine

VideoLinks
Science & Research
Overview of more VideoLinks >>>